دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 9,600,000 تومان- قیمت ویژه : 4,500,000تومان
دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
قیمت : 2,500,000 تومان- قیمت ویژه : 1,250,000تومان
Augmented intelligence and dermatology—Part I: Core concepts and applications
Augmented intelligence and dermatology—Part II: Bias, benchmarks, guidelines, ethics, regulation, and future directions
Highlights from JAAD Reviews: January 2026—The changing treatment landscape of alopecia areata
Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study
Effectiveness of biologics on synovitis and enthesitis using musculoskeletal ultrasound assessment in subclinical psoriatic arthritis: A 12-week observational real-world study
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study
Proteomic profiling reveals distinct inflammatory and neurogenic endotypes in rosacea
Caged-hypocrellin-mediated antimicrobial photodynamic therapy as a dual-action strategy for fungal clearance and immune response regulation in drug-resistant Candida auris wound infections
Chronic skin diseases and life trajectories: Development and validation of “Dermatology Long-Term Life Impact Measure�
Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial
Disparities in survival and tumor characteristics in patients with single and multiple primary Merkel cell carcinomas
Real-world treatment patterns in patients with generalized pustular psoriasis: A US-based claims study
Intralesional acyclovir versus cryotherapy in treatment of plantar warts: A randomized controlled trial
Reflectance confocal microscopy reduces biopsies in adults and children: A prospective real-life study
Prevalence, incidence, and risk factors for dermatologic conditions in people with HIV in the modern antiretroviral era: A cohort study in Washington, DC
Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial
Impact of immunosuppression on cutaneous squamous cell carcinoma outcomes
Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
Real-world effectiveness and safety of oral Janus kinase inhibitor in vitiligo: A retrospective study
Economic and environmental benefits of greening a Mohs surgery clinic: A comprehensive intervention and analysis
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study
Response to Chu et al’s “Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE− and Institute of Medicine−based recommendations�
Low-dose naltrexone for treatment of dermatologic conditions: A clinical review
Efficacy of 0.25% timolol gel in healing surgical open wounds: A randomized clinical trial
Inpatient management of hidradenitis suppurativa: A single-center retrospective study
Topical estrogen for skin aging: A systematic review of safety and efficacy
Use of oral minoxidil for androgenetic alopecia in transgender and gender-diverse people. A retrospective study of 27 patients
Impact of presenter racial/ethnic concordance on sun protection education for low-income Latine high school students: A pilot study
Cardiovascular safety of low-dose oral minoxidil in nonscarring alopecia: A multicenter population-based cohort study using TriNetX
Association between DPP4 inhibitor use and risk of skin cancer in type 2 diabetes: A real-world cohort study
Impact of clinical factors and surgical treatments on sebaceous carcinoma patients with and without Muir-Torre syndrome
Drug and vaccine-associated pemphigoid in patients aged 50 years and older: A pharmacovigilance study
Heterogeneous response to spesolimab in pyoderma gangrenosum depends on underlying myeloid disorders
A retrospective analysis of cutaneous metastasis in non-Hispanic Black and Hispanic patients
Predictors of response to anifrolumab in cutaneous lupus erythematosus: A prospective cohort study of 57 patients
Prospective cohort study comparing hidradenitis suppurativa-associated atrophic scar treatments: Fractional carbon dioxide laser versus fractional radiofrequency microneedling
Public concerns versus consumer behavior: Sunscreen use increased despite benzene and reef-safety controversies (2009-2023)
Trends and inequities in opioid prescriptions after Mohs surgery: Insights from the TriNetX network
The global burden of nonmelanoma skin cancers: A longitudinal analysis from the Global Burden of Disease Study, 1990˜2021
The impact of pulsed dye lasers on photodynamic therapy: Treatment schedules considerations for port-wine stains
Neutrophil-predominant inflammation is uncommonly seen in pyoderma gangrenosum: A retrospective review
Safety of rituximab in Mohs micrographic and dermatologic surgery: A retrospective cohort study
Efficacy and safety of abrocitinib in elderly Chinese patients with moderate-to-severe atopic dermatitis: A single-center, retrospective study
Risk factors for acne relapse and isotretinoin retreatment after initial treatment of acne vulgaris with high-dose isotretinoin: A retrospective cohort study
Adverse events of topical treatments for rosacea: A systematic review of randomized controlled trials
Germline pathogenic variants and immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors
Quick Pemphigus Disease Area Index: A simplified novel scoring system to assess disease severity in the pemphigus group of diseases
Efficacy of upadacitinib in patients with severe alopecia areata, including baricitinib-refractory cases: A case series of 22 patients
Economic and comorbidity burden of prurigo nodularis in the United States between 2017 and 2022: A retrospective matched cohort study
Five-year follow-up on randomized controlled trial of fractionated laser resurfacing as prophylaxis against actinic neoplasia
Increased bleeding complications after nasolabial interpolation flap repair with only combined antiplatelet and anticoagulation use: A retrospective, single-center experience
Risk factors for regional or distant metastatic disease in sebaceous carcinoma: A retrospective cohort study from the National Cancer Data Base
Ritlecitinib for severe alopecia areata in children under 12 years: A retrospective review of 18 cases
Risk of cutaneous T-cell lymphoma in patients with autoimmune diseases
Chemosensitization is not associated with improved adjuvant radiation outcomes for cutaneous squamous cell carcinoma: A dual-center retrospective cohort study
Diagnostic accuracy of ChatGPT in dermatology: A meta-analysis of textual versus visual prompts
Medical triage and screening deficiencies in direct-to-consumer hair loss platforms
Oral immune-related adverse events associated with PD-1 and PD-L1 inhibitor therapies: A retrospective, single-institution study
Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX
Bimekizumab in plaque type psoriasis: Meta-analyses of observational effectiveness studies
Drug reaction with eosinophilia and systemic symptoms syndrome in association with novel antineoplastic pharmacotherapy: Characterizing reported clinical patterns and outcomes utilizing the Food and Drug Administration Adverse Event Reporting System database
A decade of scleroderma wound healing: Insights from a specialized wound care center
Longitudinal cardiovascular outcomes in pyoderma gangrenosum: A propensity-matched TriNetX cohort study
Real-world characteristics of Janus kinase inhibitor-associated acne: A 14-year retrospective cohort study
Vulvovaginal involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis: A retrospective review at a tertiary care center (2016-2024)
Three-week infliximab dosing is associated with improved disease control in severe hidradenitis suppurativa: A retrospective study
Efficacy of ruxolitinib cream at different body sites in Chinese patients with nonsegmental vitiligo
Association between acneiform eruption grade and survival outcomes in EGFRi-treated metastatic colorectal cancer patients: A retrospective cohort study
Oral minoxidil 2.5 mg versus 5 mg for male androgenetic alopecia: A double-blind randomized clinical trial
Quality of life in hospitalized patients with acute generalized exanthematous pustulosis: A prospective qualitative study
A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-naïve versus systemic therapy-experienced patients
Prevalence and demographics of psoriasis in the Down syndrome population: A cross-sectional analysis using the Epic Cosmos dataset
Impact of psychiatric disease and treatment on biologic drug survival in patients with hidradenitis suppurativa
Investigation of concordance between scalp symptoms, disease severity, and inflammatory activity in scarring alopecias
Real-world safety of apremilast: A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS)
Rural-urban differences in management and survival of sebaceous carcinoma: A National Cancer Database analysis
Trends in dermatologic biologic prescribing: A Medicare Part D Public Use File analysis from 2018 to 2023
The Standard Dermatology Outcome Measures questionnaire captures improvements in dermatologic disease burden
Health insurance coverage of topical medications in vitiligo and atopic dermatitis
Low-level light therapy as a novel treatment for central centrifugal cicatricial alopecia: An interventional cohort study
Upper hair follicle transplantation combined with 308 nm excimer laser for refractory vitiligo: A promising therapeutic approach
Regional and insurance-based differences in biologic initiation for psoriasis among Medicare and commercially insured individuals in the United States: A Merative Marketscan analysis
Efficacy of Phototherapy in Managing Cutaneous Immune-Related Adverse Events in Patients Treated With Checkpoint Inhibitors
Epidemiology of sebaceous carcinoma in the United States: Analysis of Surveillance, Epidemiology, and End Results data from 2000 to 2022
Use of ritlecitinib in patients with alopecia areata refractory to tofacitinib or baricitinib: A single-center retrospective cohort study
Mapping the time course and associated factors of placebo response to systemic immunomodulatory treatments for atopic dermatitis
Comparing combination and single-agent therapy for the treatment of pemphigus: A retrospective cohort study
The efficacy and tolerability of off-label dupilumab in acantholytic dyskeratotic disorders
Association between atopic dermatitis and dermatophytosis: A TriNetX retrospective cohort study
A pilot study of CO2 laser-assisted drug delivery of hyaluronidase for the treatment of scleroderma-induced microstomia
The P2X7-NLRP3 inflammasome inhibitor AZD9056 has no significant effect on hidradenitis suppurativa clinical disease activity but restores cytokine production in peripheral blood mononuclear cells: Results of a phase 2 trial
Venous thromboembolic risk of combination therapy with intravenous immunoglobulin and Janus kinase inhibitors in dermatomyositis: A retrospective cohort study
Advocating for insurance coverage of keloids, alopecia, lupus, and sarcoidosis
Establishing consensus on defining failure of topical therapy in psoriasis: Recommendations from the International Psoriasis Council
Petrus Gonsalvus and hypertrichosis: How dermatologists help uncover the forgotten histories of marginalized individuals
New gene-based classification of ichthyoses and palmoplantar keratodermas: Hereditary epidermal differentiation disorders
The enduring impact of the American Dermatological Association on US dermatology
Older age as an independent risk factor for recurrence in stage II cutaneous melanoma
An ethical framework for managing neglected skin tumors in older patients
Ethical implications of financial incentives with academic funds for research referrals
The ethics of financial incentives to improve clinical trial diversity
Privilege or equity: Addressing favoritism in dermatology residency admissions: Balancing opportunity, equity, effort, and fairness
Dermatologists' ethical considerations of people experiencing homelessness
Ethical considerations in recommending patients avoid cosmetic treatments performed by nonphysician providers
Beyond the surface: Ethical approaches to discussing self-harm scars
Ethical implications of artificial intelligence–written personal statements in dermatology
Navigating the ethics of working with patients who refuse a psychiatry referral
Ethical implications of double-blinding peer review in academic publishing
VYJUVEK for dystrophic epidermolysis bullosa: Ethical dilemmas in access and pricing
Navigating the complexities of pharmaceutical samples and referrals
Key issues that need to be addressed to ensure the sustainability of physician-scientist careers
Response to: Key issues that need to be addressed to ensure the sustainability of physician–scientist careers
Efficacy and safety of 308-nanometer light-emitting diode phototherapy for prurigo nodularis: A randomized and self-controlled clinical trial
Response to Peng et al’s “Efficacy and safety of 308-nanometer light-emitting diode phototherapy for prurigo nodularis: A randomized and self-controlled clinical trial�
Comments on “Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis�
Response to Wang et al., “Comments on ‘Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis’�
Enhancing gender-affirming hair loss assessment: Comment on “Scalp hair parameter changes in transgender individuals commencing gender-affirming hormone therapy�
Response to “Enhancing gender-affirming hair loss assessment: Comment on “Scalp hair parameter changes in transgender individuals commencing gender-affirming hormone therapy��
Letter to “Enhanced metastatic risk stratification for cutaneous squamous cell carcinoma by combining clinical guidelines with the Erasmus MC model�
Response to Zheng et al., “Enhanced metastatic risk stratification for cutaneous squamous cell carcinoma by combining clinical guidelines with the Erasmus MC model�
Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)�
Response to: “Response to Bissonnette et al. Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy control–matched, phase 4 clinical study (BALISTAD)�
Ultralow-dose rituximab in pemphigus: Weighing clinical benefits against immunologic limitations
Response to Gupta et al, “Ultralow-dose rituximab in pemphigus: Clinical efficacy or immunologic underdosing�
Re: “Increased risk of skin cancer in mastocytosis: A large-scale retrospective cohort study of over 20,000 patients�
Response to Irshad et al, “Re: Increased risk of skin cancer in mastocytosis: A large-scale retrospective cohort study of over 20,000 patients.�
Response to Lauck et al “Cutaneous malignancy after biologic therapy for inflammatory disease: An active comparator, retrospective cohort study�
Response to Gooderham et al.’s “Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.�
Response to Hassan and Paas, “Curbing paper mills in departments and journals�
Remembering Dr Robert Sidbury: Mentor, educator, and servant leader
